A randomized, double-blind, placebo-controlled, parallel-arm Phase III trial of tesofensine in patients with obesity
Phase of Trial: Phase III
Latest Information Update: 18 Sep 2017
At a glance
- Drugs Tesofensine (Primary)
- Indications Obesity
- Focus Registrational; Therapeutic Use
- Sponsors Medix
- 18 Sep 2017 According to a Saniona media release, Medix, has recruited 150 out of the planned 372 patients in the study during the first six weeks. The company may achieve a completion of the study in less than the previously announced two years.
- 21 Aug 2017 According to a Saniona media release, the first group of patients have started the run-in period and will be randomized in August.
- 21 Aug 2017 According to a Saniona media release, this study may lead to market approval of Tesofensine in Mexico.